A Review of Tapinarof: Novel Topical Treatment for Plaque Psoriasis in Adults.
J Drugs Dermatol
; 22(8): 761-765, 2023 Aug 01.
Article
en En
| MEDLINE
| ID: mdl-37556516
ABSTRACT
Psoriasis is a chronic, immune-mediated, multisystem, inflammatory dermatological condition that is persistent and relapsing. Topical treatments are first line agents for mild to moderate plaque psoriasis. With proven efficacy and safety, topical corticosteroids are often used, although adverse effects and limitations for use exist. Tapinarof (Vtama®), a novel topical aryl hydrocarbon receptor modulating drug, was approved by the US Food and Drug Administration for the treatment of plaque psoriasis in adults in May 2022. A literature search of PubMed, MEDLINE, and ClinicalTrials.gov was conducted using the following keywords tapinarof, psoriasis, GSK2894512. Articles published before January 2023 were included in this review. This review describes the preclinical and clinical studies demonstrating the efficacy and safety of tapinarof, its place in therapy, and relevance to patient care. Kalabalik-Hoganson J, Nogid A, Frey K. A review of tapinarof novel topical treatment for plaque psoriasis in adults. J Drugs Dermatol. 2023;22(8)761-765. doi10.36849/JDD.7481.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Psoriasis
/
Estilbenos
/
Fármacos Dermatológicos
Tipo de estudio:
Diagnostic_studies
Límite:
Adult
/
Humans
Idioma:
En
Revista:
J Drugs Dermatol
Asunto de la revista:
DERMATOLOGIA
Año:
2023
Tipo del documento:
Article